Jeffery L. Kutok
No más puestos en curso
Historial de carrera de Jeffery L. Kutok
Antiguos cargos conocidos de Jeffery L. Kutok.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| EPIZYME, INC. | Director Técnico/Científico/I+D | 23/03/2020 | 01/09/2022 |
| INFINITY PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/01/2010 | 31/03/2020 |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2002 | 01/12/2010 |
| Harvard Medical School | Corporate Officer/Principal | 01/01/2002 | 01/12/2010 |
Formación de Jeffery L. Kutok.
| Stony Brook University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffery L. Kutok
- Experiencia
